Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer

Amy Soni, Edward Chu

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Several adjuvant chemotherapy regimens exist for the treatment of stage III colon cancer. In conjunction with the clinical data from randomized trials, cost-effectiveness studies might help to inform the selection of the optimal treatment regimen. In this review, the outcomes from randomized clinical trials and the elements and process of a cost-effectiveness analysis in this setting are discussed. In addition, the data from several published cost-effectiveness analysis studies in the adjuvant setting are reviewed. In general, capecitabine-based regimens have been found to be less costly and more effective than 5-fluorouracil-based regimens. The combination of oxaliplatin leads to a modestly improved effectiveness and at an acceptable incremental cost. Future studies using data obtained outside the setting of a clinical trial might help to further guide selection of the most cost-effective regimen.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalClinical colorectal cancer
Issue number4
StatePublished - Dec 2015
Externally publishedYes


  • 5-Fluorouracil
  • Capecitabine
  • Cost-effectiveness analysis
  • Oxaliplatin
  • Pharmacoeconomics
  • Stage III colon cancer

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer'. Together they form a unique fingerprint.

Cite this